Clinical Trial Update: Simulect Versus ATG in Sensitized Renal Transplant Patient [Phase 4]

View source ↗

Summary

Phase 4 trial comparing basiliximab (Simulect) versus antithymocyte globulin (ATG) in sensitized renal transplant patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Transplant Rejection

Drugs mentioned

• Simulect (Basiliximab)
• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: University Hospital, Toulouse | Conditions: Renal Transplant Rejection | Phase 4 | Status: COMPLETED